Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic

Favalli, Ennio Giulio; Maioli, Gabriella; Biggioggero, Martina; Caporali, Roberto

doi:10.1080/1744666x.2021.1908887

Cited by 13 publications

(20 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to COVID-19 global rheumatology alliance (GRA) global registry, out of 7263 COVID-19 cases, 2956 patients were documented to have RA, which is accounting to 40.7% (The COVID-19 global rheumatology alliance global registry, 2020). Other studies are in agreement with this observation and exhibited that SARS-CoV-2 infection is more prevalent in RA patients [24]. Immunosuppressant therapy was seen to be considerably associated with the risk of SARS-CoV-2 infection [22].…”

Section: Can Ra Increase the Risk Of Acquiring Covid-19 Infection?supporting

confidence: 73%

“…Patients with RA generally represent compromised immune system, which makes them susceptible to SARS-CoV-2 infection [24]. Treatment with immunosuppressant drugs further increases the risk of acquiring SARS-CoV-2 infection [22].…”

Section: Recommendation For Anti-rheumatic Drugs In the Covid-19 Settingmentioning

confidence: 99%

“…In this aspect, glucocorticoid dose and disease status have been regarded as two potential risk factors for COVID-19 severity in patients with rheumatic diseases [59]. RA patients chronically receiving glucocorticoids have been recommended to avoid sudden withdrawal of steroids and to continue their treatment with the lowest possible doses [24]. Thus, the dose of a glucocorticoid stands critical in this aspect.…”

Section: Challenges With Anti-rheumatic Agents In the Covid-19 Settingmentioning

confidence: 99%

“…According to the national health service (NHS) England, RA patients treated with bDMARDs, such as tocilizumab, rituximab, and TNF inhibitors increase the risk of acquiring SARS-CoV-2 infection compared to the patients treated with csDMARDs [28]. In contrast, others were not in agreement with the claim of NHS [24]. According to the data from GRA global registry, out of 7263 COVID-19 positive cases among rheumatic patients, 2188 (30.13%) patients were under the treatment with bDMARDs (The COVID-19 global rheumatology alliance global registry, 2020).…”

Section: Challenges With Anti-rheumatic Agents In the Covid-19 Settingmentioning

confidence: 99%

See 3 more Smart Citations

COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging association, therapeutic options, and challenges

Kandimalla¹,

Dewanjee²,

Kalra³

et al. 2021

Preprint

View full text Add to dashboard Cite

Excessive immune activation and cytokine release in alveoli/lung structures is a prominent sign of coronavirus disease 2019 (COVID-19) pathology caused by infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The progressive sign of pro-inflammatory cytokines elicited in COVID-19 clinically resembles hyper immune-reactive features often seen in rheumatoid arthritis (RA), an autoimmune disorder. Recent clinical data from the ongoing COVID-19 pandemic conferred the severity and risk of COVID-19 to RA patients. Amid the evidence of musculoskeletal manifestations involving immune-inflammation-dependent mechanisms and cases of arthralgia and/or myalgia in COVID-19, crosstalk between COVID-19 and RA is debated. The present review sheds light on the overlapping COVID-19 and RA clinical features, aspects of SARS-CoV-2 infection in RA development, and associated risks. It also confers whether RA can worsen COVID-19 outcomes based on available clinical readouts. To gain mechanistic insights into the overlapping immune-inflammatory features in SARS-CoV-2 infection and RA, we reviewed the emerging links of angiotensin-converting enzyme (ACE)-dependent and macrophage-mediated pathways. Moreover, a detailed review of immediate challenges and key recommendations for anti-rheumatic drugs in the COVID-19 setting was presented for better clinical monitoring and management of RA patients. Taken together, present review summarizes available knowledge on the emerging COVID-19 and RA crosstalk and their mechanistic overlaps, challenges, and therapeutic options.

show abstract

Section: Can Ra Increase the Risk Of Acquiring Covid-19 Infection?supporting

confidence: 73%

Section: Recommendation For Anti-rheumatic Drugs In the Covid-19 Settingmentioning

confidence: 99%

Section: Challenges With Anti-rheumatic Agents In the Covid-19 Settingmentioning

confidence: 99%

Section: Challenges With Anti-rheumatic Agents In the Covid-19 Settingmentioning

confidence: 99%

See 2 more Smart Citations

COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging association, therapeutic options, and challenges

Kandimalla¹,

Dewanjee²,

Kalra³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Furthermore, immunosuppressive agents do not appear to be linked to COVID-19 progression, so that the treatment of non-infected patients can carefully continue. However, further research is needed in order to investigate the influence of RA medications for patients infected with SARS-CoV-2, which is still controversial, so monitoring each therapeutic stage becomes essential [ 237 ].…”

Section: Therapeutic Approaches In Ramentioning

confidence: 99%

Management of Rheumatoid Arthritis: An Overview

Radu

Bungău

2021

Cells

495

185

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a multifactorial autoimmune disease of unknown etiology, primarily affecting the joints, then extra-articular manifestations can occur. Due to its complexity, which is based on an incompletely elucidated pathophysiological mechanism, good RA management requires a multidisciplinary approach. The clinical status of RA patients has improved in recent years due to medical advances in diagnosis and treatment, that have made it possible to reduce disease activity and prevent systemic complications. The most promising results were obtained by developing disease-modifying anti-rheumatic drugs (DMARDs), the class to which conventional synthetic, biologic, and targeted synthetic drugs belong. Furthermore, ongoing drug development has led to obtaining molecules with improved efficacy and safety profiles, but further research is needed until RA turns into a curable pathology. In the present work, we offer a comprehensive perspective on the management of RA, by centralizing the existing data provided by significant literature, emphasizing the importance of an early and accurate diagnosis associated with optimal personalized treatment in order to achieve better outcomes for RA patients. In addition, this study suggests future research perspectives in the treatment of RA that could lead to higher efficacy and safety profiles and lower financial costs.

show abstract

The impact of COVID-19 and other factors on the usage status of the biologic drug therapies for rheumatoid arthritis: A study from Vietnam

Bui,

Lai,

Nguyen

et al. 2024

Reumatología Clínica

View full text Add to dashboard Cite

Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic

Abstract: Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic

Cited by 13 publications

References 106 publications

COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging association, therapeutic options, and challenges

COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging association, therapeutic options, and challenges

Management of Rheumatoid Arthritis: An Overview

The impact of COVID-19 and other factors on the usage status of the biologic drug therapies for rheumatoid arthritis: A study from Vietnam

Contact Info

Product

Resources

About